Insmed (NASDAQ: INSM)
Insmed Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Insmed Company Info
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
News & Analysis
Why Shares of Insmed Are Soaring This Week
The biotech company announced positive top-line trial results and received upgrades from analysts.
Why Insmed Stock Is Soaring Today
Investors applauded the company's latest clinical results.
Why Insmed's Shares Fell 14.7% on Wednesday
The biotech company is raising money to help it launch another drug, but it's diluting current shareholders in the process.
Why Insmed Stock Is Soaring Again
Shares jump in response to a pair of analyst upgrades.
Here's Why Insmed Is Skyrocketing Today
Shares soar after Insmed reports upbeat clinical news.
Here’s Why Insmed Fell Hard Today
After a solid second quarter, investors in the biopharmaceutical company were left to wonder about management’s tepid growth forecast.
3 Biotech Stocks That Soared This Week: Are They Buys?
These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?
The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.
Valuation
Earnings Transcripts
Insmed Inc (INSM) Q3 2021 Earnings Call Transcript
INSM earnings call for the period ending September 30, 2021.
Insmed (INSM) Q1 2020 Earnings Call Transcript
INSM earnings call for the period ending March 31, 2020.
Insmed (INSM) Q4 2019 Earnings Call Transcript
INSM earnings call for the period ending December 31, 2019.
Insmed (INSM) Q3 2019 Earnings Call Transcript
INSM earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.